Thoma Bravo shuts down Imprivata process as covid-19 fears fuel market volatility

Imprivata, which helps healthcare providers protect patient information, was anticipated to command upwards of $2bn in a potential sale.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this